Impact of Adjuvant Treatment for Microscopic Residual Disease After Non-Small Cell Lung Cancer Surgery
Hancock JG, Rosen JE, Antonicelli A, Moreno A, Kim AW, Detterbeck FC, Boffa DJ. Impact of Adjuvant Treatment for Microscopic Residual Disease After Non-Small Cell Lung Cancer Surgery. The Annals Of Thoracic Surgery 2014, 99: 406-413. PMID: 25528723, DOI: 10.1016/j.athoracsur.2014.09.033.Peer-Reviewed Original ResearchConceptsNon-small cell lung cancerPositive surgical marginsCell lung cancerSurgical marginsR1 resectionNSCLC patientsResidual diseaseLung cancerNational Cancer Data BasePathologic stage IMicroscopic residual diseaseAdministration of chemotherapyOptimal treatment approachStage pIR1 patientsAdjuvant treatmentPostoperative administrationAdjuvant approachIncomplete resectionPostoperative radiationComplete resectionImproved survivalPI patientsPositive marginsSuperior survivalManagement of Clinical Stage IIIA Primary Lung Cancers in the National Cancer Database
Hancock J, Rosen J, Moreno A, Kim AW, Detterbeck FC, Boffa DJ. Management of Clinical Stage IIIA Primary Lung Cancers in the National Cancer Database. The Annals Of Thoracic Surgery 2014, 98: 424-432. PMID: 24929895, DOI: 10.1016/j.athoracsur.2014.04.067.Peer-Reviewed Original ResearchConceptsNon-small cell lung cancerNational Cancer DatabaseClinical stagingMediastinal stagingLung cancerCancer DatabaseClinical stage IIIA non-small cell lung cancerStage IIIA non-small cell lung cancerIIIA non-small cell lung cancerTreatment approachesMediastinal lymph node diseaseMediastinal lymph node metastasisClinical N2 statusTreatment-naïve patientsLymph node diseasePrimary lung cancerUse of surgeryIIIA NSCLC patientsLymph node metastasisCell lung cancerOptimal treatment approachCommon treatment approachNaïve patientsUntreated patientsMediastinal lymph